CONCISE REPORT

Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?

D Foell, M Frosch, A Schulze zur Wiesch, T Vogl, C Sorg, J Roth

Objectives: To investigate whether prolonged methotrexate (MTX) treatment after induction of remission influences the subsequent duration of remission in patients with juvenile idiopathic arthritis (JIA), and to analyse the usefulness of myeloid related proteins 8 and 14 (MRP8/MRP14) as predictive markers for the stability of remission at the time when MTX is withdrawn.

Methods: Twenty-five patients with oligoarticular and polyarticular JIA who received MTX to induce remission were followed up. MTX treatment was stopped after a mean of 3.8 months (group 1) or 12.6 months (group 2) after remission was documented. Differences in the number of relapses between these groups were looked for. Additionally, MRP8/MRP14 were analysed by ELISA in 22 patients.

Results: No difference was found in the number of relapses between patients with prolonged or early discontinued MTX treatment. Patients who were in stable remission had significantly lower MRP levels when MTX was discontinued than patients with relapses. With a cut-off point for MRP8/MRP14 at 250 ng/ml, sensitivity and specificity were 100% and 70%, respectively.

Conclusion: Longer duration of MTX treatment after induction of remission does not generally improve the status of remission in patients with JIA. Residual synovial inflammation seems to influence the rate of relapses after discontinuation of MTX treatment. MRP8/MRP14 indicate residual activity even in the absence of other laboratory or clinical signs of continuing inflammation. Normal serum concentrations of MRP8/MRP14 in clinical inactive arthritis may help to identify patients in whom MTX can be safely withdrawn after remission is achieved.

Methotrexate (MTX) is accepted to be an efficient treatment for juvenile idiopathic arthritis (JIA). Remission can be induced in most patients using combined anti-inflammatory treatment. About half of the patients have relapses or flares after discontinuation or reduction of MTX. Therefore, continuation of MTX for 12–24 months after induction of remission has been proposed, although no controlled prospective studies have been performed to investigate the impact of early discontinuation of MTX treatment on the duration of remission and the rate of relapses. It is important to know when it is safe to withdraw immunosuppressive drugs like MTX or tumour necrosis factor alpha blockers because of their potentially serious side effects. It would be unnecessary to continue these drugs in patients who are in stable and frequently lifelong remission. The rate of relapses may be influenced by residual synovial inflammation at the time when MTX is withdrawn. Unfortunately, reliable serum markers to detect such non-apparent disease activity are lacking.

To date, we have no means of identifying those clinically inactive patients at special risk for relapses. Definition of disease activity in JIA is exclusively based on clinical or routine laboratory measures. On the other hand, the rate of relapses in JIA after reduction of immunosuppressive treatment during clinical remission is high. Thus, it would be helpful to define more sensitive markers for determining the risk of remitting arthritis in JIA. Myeloid related proteins (MRP) 8 ($S100A8$) and 14 ($S100A9$) are expressed by early recruited monocytes and granulocytes. They are calcium binding proteins assembling to heterodimers. MRP8/MRP14 are secreted by infiltrating phagocytes in synovial inflammation. Serum concentrations of these proteins correlate sensitively and specifically with synovial inflammation in JIA.

In this study, we analysed clinical and laboratory parameters in 25 patients with JIA in a prospective follow-up study to evaluate the impact of the duration of MTX treatment in remission on the rate of relapses. In order to differentiate patients at special risk for relapse, we examined MRP8/MRP14 serum concentrations.

PATIENTS AND METHODS

Patients

We performed a prospective study including 25 children who fulfilled the criteria for JIA with an oligoarticular or polyarticular course of the disease. At study entry all patients had clinical symptoms of active arthritis, as defined previously. All patients received MTX (10 mg/m² body surface area) to induce remission. MTX treatment was stopped earlier than six months (group 1, 15 patients) or later than six months (group 2, 10 patients) after remission according to American College of Rheumatology (ACR) criteria had been documented. Patients were followed up over 12–36 months at intervals of 12 weeks after MTX was stopped. Table 1 summarises the characteristics of patients.

Documentation of clinical parameters

Disease activity was documented by the doctor’s global assessment and patient’s/parent’s assessment of disease activity, determination of functional ability, and the number of active joints (joint swelling or limitation of movement, with either pain on movement or tenderness). Patients were categorised as having active disease, or were considered to be in remission based on the ACR criteria for at least three consecutive months, including duration of morning stiffness not exceeding 15 minutes, no fatigue, no active arthritis, and an erythrocyte sedimentation rate (ESR) <20 mm/1st h.

Abbreviations: ACR, American College of Rheumatology; CRP, C reactive protein; ELISA, enzyme linked immunosorbent assay; ESR, erythrocyte sedimentation rate; JIA, juvenile idiopathic arthritis; MRP, myeloid related protein; MTX, methotrexate
Methotrexate treatment in JIA

Laboratory examinations

Serum concentrations of MRP8/MRP14 were determined by a sandwich enzyme linked immunosorbent assay (ELISA) following the system established in our laboratory.11 MRP8/MRP14 serum levels of 22 patients were analysed in active disease before starting MTX, and also in remission at the time when treatment with MTX was stopped. In the remaining three patients no serum was obtained at this time before starting MTX and also in remission at the start of MTX treatment. There was no serum concentrations were analysed in 22 patients with oligoarticular and polyarticular JIA before and after the start of MTX treatment. There was a significant difference between serum concentrations in active disease before starting treatment with MTX and in inactive disease after successful MTX treatment were 490 (80) ng/ml in group 1 and 2920 (970) ng/ml in group 2. Mean MRP8/MRP14 serum levels in inactive disease after successful MTX treatment were 490 (80) ng/ml in group 1 and 420 (80) ng/ml in group 2.

Predictive value of MRP levels for the risk of relapse

Patients who were in stable remission for at least one year after MTX was stopped had significantly lower MRP levels when MTX was discontinued than patients who had a relapse within one year (mean (SEM) 210 (30) ng/ml vs 590 (90) ng/ml; p = 0.01). A log rank analysis confirmed that the difference between both groups was not significant (p = 0.35). Figure 1 shows the survival analysis.

RESULTS

Relapses after discontinuation of MTX treatment

Thirteen (52%) patients had a relapse of JIA within two years after treatment with MTX was stopped. There was no difference between patients with oligoarticular or polyarticular JIA.

Influence of the time of MTX withdrawal on the rate of relapses

We found no difference in the duration of remission and the number of relapses between patients with prolonged or early discontinued MTX treatment. Seven patients (47%) had a relapse in group 1 (early withdrawal), while six patients (60%) relapsed in group 2 (late withdrawal). Within the first year after stopping MTX, the flare up rate was 33% in group 1, compared with 60% in group 2. A log rank analysis for the whole follow up period showed no significant difference for the duration of remission between the groups (0.87; p = 0.35). Figure 1 shows the survival analysis.

Serum concentrations of MRP8/MRP14

Significant reduction of MRP8/MRP14 serum concentrations in response to MTX treatment was found (fig 2A). Mean (SEM) MRP8/MRP14 serum levels in active disease before the start of MTX treatment were 2970 (1070) ng/ml in group 1 and 2920 (970) ng/ml in group 2. Mean MRP8/MRP14 serum levels in inactive disease after successful MTX treatment were 490 (80) ng/ml in group 1 and 420 (80) ng/ml in group 2.

Figure 2 Serum levels of MRP8/MRP14. (A) MRP8/MRP14 concentrations were analysed in 22 patients with oligoarticular and polyarticular JIA before and after the start of MTX treatment. There was a significant difference between serum concentrations in active disease before starting treatment with MTX and in inactive disease after successful treatment, respectively. Box plots show median, mean (bold line), 25th and 75th centiles. Error bars indicate 5th and 95th centiles (**p < 0.001). (B) MRP8/MRP14 concentrations were analysed in serum from patients in remission, obtained at the time when MTX treatment was stopped. Two groups of patients were compared according to their outcome within one year after withdrawal of MTX. Serum levels were significantly higher in patients who had a relapse within the following year than in patients who stayed in stable remission. Data points show individual MRP8/MRP14 serum concentrations. The dashed line indicates a cut off point at 250 ng/ml with a sensitivity to detect risk for a relapse of 100%, while specificity was 70% (**p = 0.01).

Table 1 Characteristics of 25 patients with JIA

<table>
<thead>
<tr>
<th>Groups</th>
<th>Early</th>
<th>Late</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>15</td>
<td>10</td>
</tr>
<tr>
<td>Diagnosis (oligoarticular/polyarticular JIA)</td>
<td>7/8</td>
<td>5/5</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>13/2</td>
<td>8/2</td>
</tr>
<tr>
<td>Age (years), mean (range)</td>
<td>6.6 (3–12)</td>
<td>6.0 (4–11)</td>
</tr>
<tr>
<td>MTX (mg/m²), mean (range)</td>
<td>9.9 (5–15)</td>
<td>10.2 (5–15)</td>
</tr>
<tr>
<td>MRP14 serum level* (months), mean (range)</td>
<td>3.8 (0–6)</td>
<td>12.6 (7–18)</td>
</tr>
<tr>
<td>Tapering before stop, No (%)</td>
<td>11 (73)</td>
<td>4 (40)</td>
</tr>
<tr>
<td>Relapses, No (%)</td>
<td>7 (47)</td>
<td>6 (40)</td>
</tr>
<tr>
<td>Duration of remission (months), mean (range)</td>
<td>14.9 (3–36)</td>
<td>12.1 (1–36)</td>
</tr>
<tr>
<td>MRP active (ng/ml), mean (SEM)</td>
<td>2970 (1070)</td>
<td>2920 (970)</td>
</tr>
<tr>
<td>MRP in remission (ng/ml), mean (SEM)</td>
<td>490 (80)</td>
<td>420 (80)</td>
</tr>
<tr>
<td>CRP active (mg/l), mean (SEM)</td>
<td>19 (9)</td>
<td>23 (7)</td>
</tr>
<tr>
<td>CRP in remission (mg/l), mean (SEM)</td>
<td>1 (1)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>ESR active (mm/1st h), mean (SEM)</td>
<td>26.5 (4.5)</td>
<td>26.9 (5.6)</td>
</tr>
<tr>
<td>ESR in remission (mm/1st h), mean (SEM)</td>
<td>9.3 (1.1)</td>
<td>12.6 (2.6)</td>
</tr>
<tr>
<td>Active joints (maximally active), mean (range)</td>
<td>3.1 (1–8)</td>
<td>5 (2–13)</td>
</tr>
</tbody>
</table>

*Continuation of treatment with MTX after diagnosis of remission was documented.
p<0.01). Figure 2B shows data for individual patients. ESR and CRP showed no difference (data not shown). With a cut off point for MRP8/MRP14 at 250 ng/ml, sensitivity and specificity were 100% and 70% for detecting a special risk for relapse, respectively. With a cut off point at 270 ng/ml sensitivity was 92%, with a specificity of 80% (positive likelihood ratio 4.6). Receiver operating curve analyses strongly suggested a diagnostic value for the risk of relapse (area under curve 0.95, 95% confidence interval 0.85 to 1.00; p<0.001), although these results have to be interpreted with care owing to the small number of patients included.

**DISCUSSION**

Our data confirm the problem of a high relapse rate after withdrawal of MTX. Taken together, 13 of our 25 patients (52%) had a relapse when MTX treatment was discontinued after clinical remission was achieved. A relapse may occur owing to new developing synovial inflammation. On the other hand, the risk of relapse may be influenced by residual synovial inflammation, even in the absence of clinical signs, when MTX is discontinued. So far, a reliable marker for such non-apparent disease activity in JIA has not been found in a prospective follow up. Our results indicate that prolonged treatment with MTX does not improve the status of remission in general. Thus, prolonged treatment with MTX for all patients, as proposed by some authors,4 5 does not generally seem to be appropriate. It is more important to identify individual patients at special risk for relapse in whom withdrawal of MTX might be harmful.

MRP8/MRP14 are released by activated phagocytes upon contact with endothelial cells in inflamed tissue.9 10 11 Their serum concentrations correlate well with local inflammation. In our study MRP8/MRP14 serum concentrations decreased significantly in response to effective treatment with MTX. However, individual differences in MRP8/MRP14 serum levels in inactive JIA point to the fact that a group of patients who are considered to be in remission according to clinical and routinely used laboratory criteria may have undetected local disease activity. These patients would be at special risk for a clinically apparent relapse of JIA as is frequently seen after withdrawal of MTX treatment.

Comparing a subgroup of patients who relapsed with those who did not, we found significantly lower serum levels of MRP8/MRP14 for the latter group. Thus, raised MRP8/MRP14 serum levels point to patients with clinically undetectable local synovial inflammation for whom prolonged treatment with MTX will be beneficial. Taking into account the high pre-test probability of 50% for a relapse after discontinuation of MTX treatment, a likelihood ratio of 4.6 results in a substantial shift of the post-test probability to about 85% in the presence of high MRP8/MRP14 levels.3

Although our study group is relatively small these data demonstrate that MRP8/MRP14 are markers for clinically non-apparent disease activity. Further prospective studies have to prove that MRP8/MRP14 serum levels may be used to guide anti-inflammatory treatment in JIA. So far, the impact of the time point of MTX discontinuation on the risk for relapses has not been studied systematically. We cannot exclude the possibility that reasons related to patient characteristics influenced the decision for stopping MTX earlier or later, and that this might have influenced the subsequent occurrence of flares. Therefore, a controlled randomised study will be necessary to analyse if treatment with MTX can be safely stopped once individual patients have reached a status of remission without signs of residual synovial inflammation.

**ACKNOWLEDGEMENTS**

We thank Heike Harter for excellent technical assistance.

**REFERENCES**

Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?

D Foell, M Frosch, A Schulze zur Wiesch, T Vogl, C Sorg and J Roth

doi: 10.1136/ard.2003.005686

Updated information and services can be found at:
http://ard.bmj.com/content/63/2/206

These include:

**References**

This article cites 15 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/63/2/206#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Immunology (including allergy) (5144)
- Inflammation (1251)
- Connective tissue disease (4253)
- Rheumatoid arthritis (3258)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/